CSL Limited (ASX: CSL) reported total revenue of US$8.332 billion for the half year ended 31 December 2025, reflecting a 2% decline compared to the prior period. Reported NPAT attributable to shareholders fell sharply to US$401 million due to significant restructuring and impairment charges, while underlying NPATA declined 6% to US$1.946 billion.
The performance was impacted by policy changes, generic competition, and more than US$2.0 billion in restructuring and impairment expenses. Despite this, cash flow from operations remained strong at US$1.3 billion, supporting an expanded share buy-back program and an interim dividend of US$1.30 per share. Management continues executing a broad transformation program focused on operational simplification, cost efficiency, and targeted growth investments. The company maintains FY26 guidance of approximately 2–3% revenue growth and 4–7% NPATA growth at constant currency, underpinned by expected momentum in immunoglobulin, albumin, and recently launched products in the second half.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
CSL Limited: Transformation Underway Amid Short-Term Earnings Pressure
CSL Limited (ASX: CSL) reported total revenue of US$8.332 billion for the half year ended 31 December 2025, reflecting a 2% decline compared to the prior period. Reported NPAT attributable to shareholders fell sharply to US$401 million due to significant restructuring and impairment charges, while underlying NPATA declined 6% to US$1.946 billion.
The performance was impacted by policy changes, generic competition, and more than US$2.0 billion in restructuring and impairment expenses. Despite this, cash flow from operations remained strong at US$1.3 billion, supporting an expanded share buy-back program and an interim dividend of US$1.30 per share. Management continues executing a broad transformation program focused on operational simplification, cost efficiency, and targeted growth investments. The company maintains FY26 guidance of approximately 2–3% revenue growth and 4–7% NPATA growth at constant currency, underpinned by expected momentum in immunoglobulin, albumin, and recently launched products in the second half.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au